

10^8 M^{-1} , wherein said humanized immunoglobulin comprises amino acids from the donor immunoglobulin framework outside both the Kabat CDRs and the structural loop CDRs of the variable regions, wherein the donor amino acids replace corresponding amino acids in the acceptor immunoglobulin heavy or light chain frameworks, and each of said donor amino acids is adjacent to a CDR in the donor immunoglobulin sequence or contributes to antigen binding as determined by X-ray crystallography.

28. (Amended) A humanized immunoglobulin having complementarity determining regions (CDRs) from a donor immunoglobulin and heavy and light chain variable region frameworks from human acceptor immunoglobulin heavy and light chains, which humanized immunoglobulin specifically binds to an antigen with an effective antigen binding affinity, wherein said humanized immunoglobulin comprises amino acids from the donor immunoglobulin framework outside both the Kabat CDRs and the structural loop CDRs of the variable regions, wherein the donor amino acids replace corresponding amino acids in the acceptor immunoglobulin heavy or light chain frameworks, and each of said donor amino acids is adjacent to a CDR in the donor immunoglobulin sequence or contributes to antigen binding as determined by X-ray crystallography.

29. (Amended) A humanized immunoglobulin according to claim 28 which specifically binds to an antigen with a binding affinity [equivalent to that of a chimeric antibody formed from] similar to that of said donor immunoglobulin.

REMARKS

This paper is being filed in response to the Office Action dated November 16, 1998. A petition for a two-month extension of time and the appropriate fee accompany this response.

Claims 24-31 are pending. In the Office Action, all pending claims were rejected. In view of the foregoing amendments and the arguments that follow, Applicants